Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02149108 · ClinicalTrials.gov registry record · Phase 3
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 768
- Enrollment target
NCT02149108 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 768 participants.
The verdict
NCT02149108, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 768 participants
- Enrollment target
Study Summary
The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard chemotherapy and biological agents.
Interventions
- DRUG Placebo
- DRUG BSC
- DRUG Nintedanib (BIBF 1120)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 768 participants |
| Start Date | 2014-09-25 |
| Est. Completion | 2016-08-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02149108
The ClinicalTrials.gov registry entry for NCT02149108 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 768 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02149108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02149108 about?
NCT02149108 is a clinical study titled "Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)". The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard chemotherapy and biological agents.
What is the current status of trial NCT02149108?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 768 participants. The study started on 2014-09-25. Estimated completion is 2016-08-25.
What interventions are being tested in trial NCT02149108?
The interventions under investigation include: Placebo (DRUG), BSC (DRUG), Nintedanib (BIBF 1120) (DRUG).
Who is sponsoring clinical trial NCT02149108?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.